PAK2 Antibody
Code | Size | Price |
---|
PSI-3887-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-3887-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
PAK2 Antibody: PAK65, PAKgammaGamma-PAK, PAK-2
Application Note:
WB: 0.5-2 μg/mL; IHC: 10 μg/mL; IF: 20 μg/mL.
Antibody validated: Western Blot in human, mouse and rat samples; Immunohistochemistry and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human, mouse and rat samples; Immunohistochemistry and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
PAK2 Antibody: The p21-activated kinases (PAKs) are serine-threonine kinases that bind to the active forms of Cdc42 and Rac. They are divided into two groups, the first of which include PAK1, 2 and 3, and can be activated by Cdc42/Rac binding. Group 1 PAKs contain an autoinhibitory domain whose activity is regulated by Cdc42/Rac binding. The group 1 PAKs are known to be involved in cellular processes such as gene transcription, apoptosis, and cell morphology and motility. Much less is known about the second group, which includes PAK4, 5 and 6, and are not activated by Cdc42/Rac binding. Of the six PAK proteins, only PAK2 is ubiquitously expressed and cleaved by caspase-3. This cleavage removes the amino-terminal regulatory domain and generates a constitutively active kinase fragment. Recent experiments have shown that following cleavage, the active fragment is myristoylated and directed to the plasma membrane and membrane ruffles where it promotes cell death via increased signaling through the c-Jun N-terminal kinase pathway, but without compromising mitochondrial integrity.
Background References:
- Jaffer and Chernoff. Int. J. Biochem. Cell Biol. 2002; 34:713-7.
- Rudel and Bokoch. Science 1997; 276:1571-4.
- Vilas, et al. Proc. Natl. Acad. Sci. USA 2006; 103:6542-7.
Buffer:
PAK2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Rabbit: (93%)
Immunogen:
Anti-PAK2 antibody (3887) was raised against a peptide corresponding to 14 amino acids near the amino terminus of human PAK2.
The immunogen is located within amino acids 20-70 of PAK2.
The immunogen is located within amino acids 20-70 of PAK2.
ISOFORMS:
Human PAK2 has only one isoform (524aa, 58kD). Mouse PAK2 has one isoform (524aa, 58kD) and rat PAK2 also has one isoform (524aa, 58kD). 3887 can detect the isoforms of human, mouse and rat.
NCBI Gene ID #:
5062
NCBI Official Name:
p21 protein (Cdc42/Rac)-activated kinase 2
NCBI Official Symbol:
PAK2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 58kD
Observed: 58 kD
Observed: 58 kD
Protein Accession #:
NP_002568
Protein GI Number:
32483399
Purification:
PAK2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction,Apoptosis,Cancer
Swissprot #:
Q13177
User NOte:
Optimal dilutions for each application to be determined by the researcher.
VALIDATION:
Independent Antibody Validation in Cell lines (Figure 2) shows similar PAK2 expression profile in human, mouse and rat cell lines detected by two independent anti-PAK2 antibodies that recognize different epitopes, 3885 against C-terminus domain and 3887 against N-terminus domain. PAK2 proteins are detected in the most tested cell lines at different expression levels by the two independent antibodies.
Related Products
Product Name | Product Code | Supplier | PAK2 Peptide | PSI-3887P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|